Investigated for treating COVID-19.
Also contra-indicated in patients with idiopathic pulmonary fibrosis.
- TRADE NAMES: Letairis (Gilead); Volibris (GSK)
- INDICATIONS: Pulmonary arterial hypertension
- CLASS: Antihypertensive, Endothelin receptor (ETR) antagonist, Vasodilator
- HALF-LIFE: 9 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Conivaptan, Cyclosporine, CYP2C19 inducers or inhibitors, CYP3A4 inducers or inhibitors, Dasatinib, Deferasirox, Grapefruit Juice, St John's Wort
- See adverse reactions attributed to class:
CONTRA-INDICATED IN PREGNANCY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ambrisentan in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
